JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.'
The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families.
For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities.
Learn more about JCR, its technologies, and clinical development programs on its global website: https://jcrpharm.com/.
About the J-Brain Cargo ® Platform Technology
JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa).
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: https://jcrpharm.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
5 hours ago
- New York Post
Boeing machinists reject new contract as company now preps for imminent strike
Union members who assemble Boeing's fighter jets in the St. Louis area have 'overwhelmingly voted' to reject the company's contract offer on Sunday, with the company now preparing for an imminent strike. Boeing's proposal, which was sent on Tuesday to more than 3,200 members of the International Association of Machinists and Aerospace Workers District 837, included a 20% general wage increase over four years and a $5,000 ratification bonus, as well as more vacation time and sick leave. 'The proposal from Boeing Defense fell short of addressing the priorities and sacrifices of the skilled IAM Union workforce,' the union said. 3 Boeing 737 MAX aircraft are assembled at the companys plant in Renton, Washington, US June 25, 2024. via REUTERS 3 An employee works on the fuselage of a Boeing 737 MAX 9 test plane. outside the company's factory, on March 14, 2019 in Renton, Washington. Getty Images Dan Gillian, Boeing's Air Dominance vice president, general manager and senior St. Louis Site executive said in an emailed statement that it is disappointed Boeing employees voted down 'the richest contract offer we've ever presented to IAM 837 which addressed all their stated priorities.' 'We've activated our contingency plan and are focused on preparing for a strike. No talks are scheduled with the union,' Gillian added. 3 This graphical rendering provided by the U.S. Air Force shows the Next Generation Air Dominance (NGAD) Platform, the F-47. On Friday, March 21, 2025. AP The current contract expires on Sunday following which there is a seven-day cooling off period before a strike would begin, the union added. Boeing's defense division is expanding manufacturing facilities in the St. Louis area for the new US Air Force fighter, the F-47, after it won the contract earlier this year. The Next Generation Air Dominance fighter jet program, initially conceived as a 'family of systems' centered around a sixth-generation fighter jet, is meant to replace the F-22 Raptor.
Time Business News
18 hours ago
- Time Business News
New Advances in IAHA Injections for Orthopedic Care
Orthopedic intra-articular hyaluronic acid (IAHA) injection is a treatment where a natural substance found in hyaluronic acid-format fluid is injected into a joint, most commonly to relieve pain, pain, pain and improve mobility in patients with chronic osteoarthritis. The future of orthopedic intra-articular hyaluronic acid (IAHA) injection market looks promising the future, cases of increasing osteoarthritis, the patient's priority for non-surreal treatment, and is inspired by innovations in long-lasting ha formulations. Extending access to emerging markets such as outpatient settings, favorable regulatory support, and Asia-Pacific will further boost demand for increase in demand. Advances such as combination therapy and better distribution methods are also expected to increase the results of treatment and make market access wider. Key Growth Drivers and Opportunities Growing Demand for Minimally Invasive Treatments: Orthopedic intra-articular hyaluronic acid (IAHA) injection market growth primarily due to the rise in the demand for minimally invasive treatments. The main factor is that individuals are more and more turning to fast, safe, and efficient options that do not interfere with their lifestyle. These patients,' electromechanical effector haptic display (EEHD), 'also benefit from a significantly lower recovery time, a crucial aspect when outpatient surgery is concerned. This is why patients and doctors are attracted to this method of treating because it is not only a one-time, surgical method but also a follow-up procedure in most cases by healthcare professionals. Challenges The hyaluronic acid injection field of orthopedics (HA) intra-articular is a limited market. Firstly, in the situation of inconsistent clinical outcomes, not all patients are able to get significant pain relief or improvement in mobility. This is about patients facing the clinical side effects from drugs given by a doctor. Apart from that, the high cost of treatment and the restriction of the purchasing power or the non-reimbursable insurance process will lead to the restraining of the use of the treatment of the patients. The issue of the temporary relief of symptoms will often encourage medication over longer periods, but the need for repetitive injections can serve as a deterrent. Innovation and Expansion JOYCLU, A Monthly Intra-Articular Injection for Osteoarthritis Relief, is introduced by Ono and Seikagaku In May 2021, the joint function improvement drug JOYCLU 30mg Intra-articular Injection (generic name: diclofenac etalhyaluronate sodium; 'JOYCLU') was introduced by Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation. Seikagaku was granted manufacturing and marketing approval in Japan for this product. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks. Hyaluronic acid and the anti-inflammatory medication diclofenac are chemically bound in the JOYCLU formulation by Seikagaku's in-house technology. It is intended to hydrolyze diclofenac in the joint and release it. The intra-articular injection of JOYCLU, which is authorized for the treatment of osteoarthritis (hip and knee joints), is anticipated to alleviate osteoarthritis symptoms once every four weeks. Inventive Sparks, Expanding Markets Multiple key players currently conduct business in the orthopedic intra-articular hyaluronic acid (IAHA) injection market, for instance, Anika Therapeutics, Inc., Zimmer Biomet, Ferring, LG Chem, Bioventus LLC, and others. By introducing new products, getting involved in the market, teaming up thereby forming partnerships, and through patient education and reimbursement means which also enhance patient access, IAHA-based injectable companies are in the process of their growth. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Business Insider
2 days ago
- Business Insider
How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life
Biopharma giant Johnson & Johnson's (JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving the market a clear signal that it's reigniting growth with practically flawless numbers—a potential turning point for the second half of the year. The upwardly revised guidance and expectations for strong margin expansion, despite lingering litigation concerns, have brought fresh optimism to the stock and appeased shareholders clamoring for added value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. While the stock isn't as discounted as it was earlier this year, valuations still look reasonable. Given JNJ's strong compounding potential and this renewed bullish momentum, I see it as a Buy. How J&J's Strong Quarter Sets the Stage for Growth Johnson & Johnson stock has been rangebound for years, weighed down by a mix of factors, including a massive wave of lawsuits claiming its talc-based baby powder caused cancer due to asbestos contamination, as well as expiring drug patents, such as its blockbuster Stelara losing exclusivity. Last but not least is sluggish growth and an eroded safe-haven reputation, since legacy consumer brands like Tylenol, Listerine, and Band-Aid have low growth and face margin pressure from cheap competition. According to TipRanks data, JNJ has underperformed the S&P quite considerably since 2024. Johnson & Johnson's latest Q2 earnings may mark a true inflection point toward more consistent alpha generation. The company delivered exactly what it needed— beating both earnings and revenue expectations —while issuing a notable upward revision to guidance: an additional $2 billion in forecasted sales and $0.25 more in projected EPS. For a pharma giant like J&J, that's a clear signal of renewed momentum following a prolonged period of litigation-related overhang. Management also reaffirmed its full-year outlook for a 300-basis-point improvement in operating margin, raising it from approximately 25.4% to 28.4%. Notably, the quarter wasn't just about numbers. J&J reported compelling 5-year trial results for its multiple myeloma immunotherapy—an encouraging sign in the fight against a challenging cancer. The company also set an ambitious goal: to become the global leader in oncology by 2030, with a target of over $50 billion in cancer drug sales. With a potential $5 billion peak opportunity in bladder cancer and a strong pipeline aimed at offsetting losses from aging blockbusters, J&J is signaling that real innovation is back at the forefront. Breaking Free from the Margin Squeeze While markets often reward margin expansion, Johnson & Johnson looks especially well-positioned to benefit going forward. In addition to raising full-year earnings guidance, the company also delivered positive updates on cost pressures— halving its expected tariff impact from $400 million to $200 million and projecting a $1.1 billion tailwind from favorable currency shifts as the U.S. dollar weakens. The reduced tariff burden is primarily attributed to the MedTech division, which is more exposed to global supply chains and international manufacturing than the pharmaceutical segment. That's a clear tailwind for margins and future profitability. It's also important to note how strategic portfolio decisions have helped set the stage for this improvement. The 2023 spin-off of Kenvue—essentially the entire Consumer Health business—removed a lower-margin segment from the mix, sharpening J&J's focus on higher-margin areas. This move highlights the company's commitment not only to defending margins but also to actively growing them. In today's market, stability alone isn't enough—investors are looking for real margin expansion, and Johnson & Johnson seems intent on delivering. Analysts have responded by raising their EPS estimates for 2025 and 2026 by about 2% compared to before Q2 earnings. They now expect full-year EPS in 2025 to hit $10.86 —an 8.7% increase from last year—and to reach $11.34 in 2026, representing an annual growth rate of 4.4%. Reasonable Valuation with Growth on the Horizon Johnson & Johnson is a vast, stable, and diversified company, so its valuation tends to reflect relative stability rather than wild growth. Looking at its forward earnings multiple, currently around 15.5x, it's basically in line with the five-year average. This is well above the lows seen earlier this year, when it traded as low as 11x forward earnings in January. To me, this suggests the valuation isn't necessarily cheap, but it's reasonable. Comparing J&J's current earnings multiples over the last twelve months to its main peers, the 17.5x P/E ratio sits close to the sector average. Except for Merck & Co. (MRK), J&J is actually one of the more discounted names in the group. Finally, with a dividend yield of almost 3%, the stock no longer appears exuberant, and the yield isn't particularly compelling—especially when compared to the 10-year U.S. Treasury yield. However, J&J's payout ratio is typically safe, at around 50% of earnings, which helps build shareholder trust. Additionally, the market is now anticipating a more positive growth trajectory following the recent upward revisions to guidance, both last quarter and earlier this year. Is JNJ Stock a Buy, Hold, or Sell? Wall Street sentiment on Johnson & Johnson remains mixed, with more caution than conviction among analysts. Of the 19 analysts who have issued ratings over the past three months, nine are bullish, while the remaining ten are neutral. The average price target stands at $176.35, suggesting a modest upside of approximately 4.3% from the current share price. Johnson & Johnson Positioned for Consistent Alpha Generation Johnson & Johnson has, in my view, successfully restored market confidence in both its innovation pipeline and cost discipline—key pillars that could drive renewed growth and support reliable shareholder returns for decades to come. For long-term investors, initiating a position now is essentially a bet on a proven dividend combined with steady capital appreciation—an attractive formula that has historically outperformed the broader market. While the stock appears fairly valued at current levels, it offers compelling potential for compounding returns and consistent alpha generation in the years ahead.
